Social Media Ideas for Indivior Pharmaceuticals

Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company

M&A activity is going beyond big pharma acquisitions with Supernus Pharmaceuticals and Indivior Pharmaceuticals reaching a stock deal that the companies call a merger of equals...

Supernus, Individor merge to beef up brain drug portfolio

The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Pa...

Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide

Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.

Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma

Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor lande...

Pfizer-backed Priovant wins FDA approval for lead asset

Ideal Option Releases 2025 Patient Outcomes Annual Report, Highlighting Life-Saving Impact Amid Ongoing Opioid Crisis in...

New data show 96% opioid abstinence rates among long-term patients as the state reports its first multi-year decline in overdose deaths since the fentanyl crisis began. LITTLE ROCK...

AbbVie Seeks Block On Alkem Generic Constipation Drug

AbbVie Inc. and collaborator Ironwood Pharmaceuticals urged a New Jersey federal court to bar India-based generic drugmaker Alkem Laboratories from selling generic versions of thei...

Lilly Claims 6 Vendors Illegally Sold Obesity Drug Candidate

Eli Lilly & Co. hit a medical spa business, compounding pharmacy and a group of chemical suppliers with claims they're illegally selling an obesity drug candidate Lilly is rese...

<![CDATA[Eli Lilly to Acquire AtaiBeckley for $2.8 Billion ]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Simtriyo]]>

<![CDATA[Licensing Roundup: Biohaven & SK Biopharmaceuticals Enter Deal for BHV-7000, Haisco License’s Sentivera...

<![CDATA[FDA Approves Otsuka’s First-In-Class Simtriyo for Adults & Pediatric Patients ]]>

July 15 2026 - Sun Pharma wins South Africa approval to launch generic Ozempic

July 15 2026 - Sun Pharma wins South Africa approval to launch generic Ozempic admin Wed, 07/15/2026 - 12:37 Innovation remained front and center today, with progre...

<![CDATA[Pharmaceutical Executive Daily: Novo Nordisk Files Lawsuit Against Eli Lilly]]>

Eli Lilly Launches Attacks On Tirzepatide Generics

Eli Lilly and Co. fired off a round of lawsuits in Delaware federal court seeking to block generic versions of its tirzepatide weight loss and diabetes medications, targeting Sando...

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences]]>

<![CDATA[Eli Lilly Surpasses Wall Street Estimates on Injectable GLP-1 Drugs]]>

Pain drugmaker Latigo outlines plans to go public

The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.

Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads

Danish pharma company says Eli Lilly using outdated trial data to make its weight-loss drugs appear more effectiveOzempic maker Novo Nordisk said on Tuesday it is suing arch US riv...

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

Novo's False Ad Suit Against Eli Lilly Ramps Up GLP-1 Rivalry

Pharmaceutical giant Novo Nordisk Inc. slapped rival Eli Lilly & Co. with a false advertising suit in New Jersey federal court Tuesday, calling a marketing campaign for the riv...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Viatris's Gwyn Lo]]>

Compounders maintain a firm grip on the GLP-1 market

Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.

<![CDATA[Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons]]>